Current patent status of histone deacetylase inhibitors

Bibliography

• CHEUNG WL, BRIGGS SD, ALLIS CD: Acetylation and chromosomal functions. Curc Opin. Cell Biol. (2000) 12:326–333.
   PubMed Web of Science ®Google Scholar
• VIGUSHIN DM, COOMBES RC: Histone deacetylase inhibitors in cancer treatment. Anticancer Drugs (2002) 13:1–13.
   PubMed Web of Science ®Google Scholar
• GRAY SG, EKSTROM TJ: The human histone deacetylase family. Exp. Cell Res. (2001) 262:75–83.
   PubMed Web of Science ®Google Scholar
• ••A thorough summary of HDAC classes aswell as the surtuins.
   Google Scholar
• KRAMER OH, GOTTLICHER M, HEINZEL T: Histone deacetylase as a therapeutic target. Trends in Endocrin. & Metab. (2001) 12:294–300.
   PubMed Web of Science ®Google Scholar
• •Includes a summary of tumour cell lines and genes which are affected by HDAC inhibitors.
   Google Scholar
• JUNG M: Inhibitors of histone deacetylase as new anticancer agents. Curr. Med. Chem. (2001) 8:1505–1511.
   PubMed Web of Science ®Google Scholar
• STERNSON SM, WONG JC, GROZINGER CM, SCHREIBER SL: Synthesis of 7200 small molecules based on a substructural analysis of the histone deacetylase inhibitors trichostatin and trapoxin. Org. Lett. (2001) 3:4239–4242.
   PubMed Web of Science ®Google Scholar
• FINNIN MS, DONIGIAN JR, COHEN A et al.: Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature (1999) 401:188–193.
   PubMed Web of Science ®Google Scholar
• ••The only structural study of bound HDACinhibitors published to date.
   Google Scholar
• RICHON VM, EMILIANI S, VERDIN Eet al.: A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Nati Acad. Sci. USA (1998) 95:3003–3007.
   Google Scholar
• •Early biological characterisation of an HDAC inhibitor.
   Google Scholar
• KELLY WK, RICHON V, TROSO-SAND OVALT et al.: Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor: biologic activity without toxicity. Proc. Am. Soc. Clin. Oncol. (2001) 20(87a):344.
   Google Scholar
• JUNG M, BROSCH G, KOLLE D, SCHERF H, GERHAUSER C, LOIDL P: Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. I Med. Chem. (1999) 42:4669–4679.
   PubMed Web of Science ®Google Scholar
• OHTANI M, MATSUURA T, SHIRAHASE K, SUGITA K: (2E)-543-[(Phenylsulfonyl) amino] phenyllpent- 2-en-4-ynohydroxamic acid and its derivatives as novel and potent inhibitors of ras transformation.j Med. Chem. (1996) 39:2871–2873.
   Google Scholar
• KIM YB, LEE K, SUGITA K, YOSHIDA M, HORINOUCHI S: Oxamflatin is a novel antitumour compound that inhibits mammalian histone deacetylase. Oncogene (1999) 18:2461–2470.
   PubMed Web of Science ®Google Scholar
• SU GH, SOHN TA, RYU B, KERN SE: A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Res. (2000) 60:3137–3142.
   PubMed Web of Science ®Google Scholar
• LAVOIE R, BOUCHAIN G, FRECHETTE S et al.: Design and synthesis of a novel class of histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. (2001) 11:2847–2850.
   PubMed Web of Science ®Google Scholar
• MEINKE PT, LIBERATOR P: Histone deacetylase: a target for antiproliferative and antiprotozoal agents. Carr. Med. Chem. (2001) 8:211–235.
   PubMed Web of Science ®Google Scholar
• ••Includes a chemical and biological review ofall the HDAC structural classes.
   Google Scholar
• SINGH SB, ZINK DL, LIESCH JM et al: Structure and chemistry of apicidins, a class of novel cyclic tetrapeptides without a terminal a-keto epoxide as inhibitors of histone deacetylase with potent antiprotozoal activities.' Org. Chem. (2002) 67:815–825.
   PubMed Web of Science ®Google Scholar
• •Includes a complete listing of all Merck tetrapeptide publications.
   Google Scholar
• FURUMAI R, KOMATSU Y, NISHINO N, KHOCHBIN S, YOSHIDA M, HORINOUCHI S: Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. USA (2001) 98:87–92.
   PubMed Web of Science ®Google Scholar
• •The only publication of Class II HDAC activities (HDAC4 and HDAC6) to date.
   Google Scholar
• SANDOR V, BAKKE S, ROBEY RW et al.: Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin. Canc. Res. (2002) 8:718–728.
   PubMed Web of Science ®Google Scholar
• NAKAJIMA H, KIM YB, TERANO H, YOSHIDA M, HORINOUCHI S: FR901228, a potent antitumour antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell Res. (1998) 241:126–133.
   PubMed Web of Science ®Google Scholar
• MICHAELIDES MR, CURTIN ML: Recent advances in matrix metalloproteinase inhibitors research. Carr. Pharm. Design (1999) 5:787–819.
   PubMed Web of Science ®Google Scholar
• SAITO A, YAMASHITA T, MARIKO Y et al.: A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumour activity against human tumours. Proc. Nati Acad. Sci. USA (1999) 96:4592–4597.
   PubMed Web of Science ®Google Scholar
• SUZUKI T, ANDO T, TSUCHIYA K et al.:Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives.' Med. Chem. (1999) 42:3001–3003.
   Web of Science ®Google Scholar
• SEELIG MH, BERGER MR: Efficacy of dinaline and its methyl and acetyl derivatives against colorectal cancer in vivo and M vitro. Eur. Cancer (1996) 32A:1968–1976.
   PubMedGoogle Scholar
• KRAKER AJ, HARTL BG, MIIN J, MERRIMAN RL: Effect of CI-994 (N-acetyl dinaline or 4- (acetylamino)- N- (2-amino-phenyl)benzamide) on histone acetylation and differentiation in HCT-8 colon carcinoma cells. Proc. Am. Assoc. Canc. Res. (1999) 40(90):121–122.
   Google Scholar
• PRAKASH S, FOSTER BJ, MEYER M et al.: Chronic oral administration of CI-994: a Phase I study. Invest. New Drugs (2001) 19:1–11.
   PubMed Web of Science ®Google Scholar
• WARRELL RP Jr, HE L, RICHON V, CALLEJA E, PANDOLFI PP: Therapeutic targeting of transcription in acute promyelocytic leukaemia by use of an inhibitor of histone deacetylase." Nat. Canc. Inst. (1998) 90:1621–1625.
   PubMedGoogle Scholar
• REPHAELI A, ZHUK R, NUDELMAN A: Prodrugs of butyric acid from bench to bedside: synthetic design, mechanisms of action and clinical applications. Drug Development Res. (2000) 50:379–391.
   Web of Science ®Google Scholar
• ••A thorough review of the butyric acidprodrug concept and practice.
   Google Scholar